Skip to main content
GoodMoatv1.3
Sign in
AFMD logo

AFMD

CompareEarnings: Mar 2, 2025

Affimed N.V.

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in EUR

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Did you know?

Price sits at 13% of its 52-week range.

Current Price

$0.18

+0.00%
Profile
Valuation (TTM)
Market Cap$2.78M
P/E-0.03
EV—
P/B0.04
Shares Out15.30M
P/Sales2.88
Revenue$965180.77
EV/EBITDA—

Affimed N.V. (AFMD) Company Profile

AFMD Company Information

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system.

The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors.

ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells.

A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy.

Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives.

For more about the Company’s people, pipeline and partners, please visit: www. affimed. com.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Germany

AFMD Key Officers

Key officers data coming soon

AFMD Company Profile

Affimed N.V. (AFMD) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Germany.

Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Market cap is $2.78M. There are 15.3M shares outstanding.

See the full Affimed N.V. profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if AFMD is a good investment.